教育经历:
1994.09-1998.07 山东农业大学，植物保护系，农学学士
1998.09-2001.07 山东农业大学，植物保护系，农学硕士
2001.09-2004.07 南开大学，微生物系，理学博士
工作经历:
2005.08-2009.07: 博士后，亚利桑那州立大学生物设计学院感染疾病及疫苗研究中心
2009.08-2012.01: 助理研究员，亚利桑那州立大学生物设计学院感染疾病及疫苗研究中心
2012.02-2015.07: 助理教授（研究），亚利桑那州立大学感染疾病及疫苗研究中心
2015.08-2017.09: 副教授（研究），佛罗里达大学兽医学院感染疾病及病理学系
2013.01-2015.09: 兼职研究员，四川农业大学动物医学院预防兽医研究所
2015.10-2017.08: 客座研究员，四川农业大学动物医学院预防兽医研究所
2017.09- ：教授，西南大学mobile288-365
专业会员及学术服务:
会员：美国微生物学会及国际内毒素及先天免疫学会
20多种期刊的审稿人:
1. Vaccine
2. Biotechnology and Bioengineering
3. Virulence
4. Infection and Immunity
5. Journal of Applied Microbiology
6. Letters in Applied Microbiology
7. Journal of Fish Diseases
8. Veterinary Microbiology
9. Journal of Bacteriology
10. PLOS One
11. Microbial Drug Resistance
12. Current microbiology
13. Molecular Microbiology
14. Oncotarget
15. PNAS
16. Scientific Report
-------
以下基金的评审人:
1. 2013-现在, 中国自然科学基金：青年项目，地区项目，面上项目，优秀青年项目，国际合作项目.
2. 2013-现在, 中国博士后基金
3. 2014, 盖茨基金
4. 2016, 美国国立卫生研究院R01项目
5. 2017, 波兰科学基金
研究项目（仅列本人为主持人的项目）
中国基金：
1. 自然基金面上项目(31270981),2013.01-2016.12(已结题).
2. 自然基金面上项目(31570928),2016.01-2019.12(在研).
3. 四川省杰出青年科学基金(2014JQ0006),2014.01-2017.12(在研).
4. 四川省百人计划项目.
美国基金:
1. 美国国立卫生研究院 R21-AI-100199, 07/01/2012-06/30/2015(已结题).
2. 美国国立卫生研究院 R21-AI-098081, 08/01/2012-07/30/2015 (已结题).
3. 美国国立卫生研究院 R01-AI-112680, 08/01/2015-01/30/2020(在研)
学术成绩：
本人的工作主要集中在疫苗研发，属于应用科学，转化医学（兽医学）领域。申请专利保护及获得产品入市是核心。获批2项中国专利及2项美国专利（国际专利），其中一个针对新生儿的减毒沙门预防肺炎感染的疫苗已经进行了一期临床试验，本人也参与其中，目前正在申请的中国专利有10项。目前已经发表第一作者或通讯作者SCI文章20多篇，其它合作文章10多篇。其中一篇作为封面论文和热点评论发表在美国免疫学杂志，3篇论文被美国微生物学会旗下的“Microbe magazine”重点报道，该杂志每年仅12期，报道目前研究热点和创新性工作，每期仅选择美国微生物学会旗下10多种期刊中的4-6篇文章重点报道。文章发表在国际领域的专业主流期刊，Vaccine, Infection and Immunity, Journal of Immunology, International journal of Medical Microbiology，Veterinary Microbiology, Scientific Report, Cell等。
期刊文章(*, 通信作者)
1. Pei Li, Qing Liu, Hongyan Luo, Roy Curtiss III, Qingke Kong*, Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuated Salmonella Typhimurium induce strong immune responses against these two antigens, submitted to Npj vaccines, under review
2. Pei Li, Qing Liu, Hongyan Luo, Qingke Kong*, O-serotype conversion in Salmonella Typhimurium induces protective immune responses against invasive non-typhoidal Salmonella infections, Frontier in Immunology, under review.
3. Yue Han, Qing Liu, Qingke Kong*, Attenuated Salmonella Typhimurium delivering avian pathogenic Escherichia coli O1 O-antigen polysaccharide induces immune responses and provides protection against challenge of infection, Pathogens and Diseases, online.
4. Xinin Zhao, Dai Q, Liu M, Yang Q, Kong Q*, and Jia R* (co-corresponding author). Recombiant atteuanted Salmonella Typhimurium with heterologous expression of the Salmonella Choleraesuis O-polysaccharide, Sci Rep, 2017, 7(1):7127,
5. Bo Hu, Lara-Teiero M, Qingke Kong, JE Galan, J Liu, In situ molecular architecture of the Salmonella type III secretion machine, Cell, 2017, 168(6): 1065-1074.
6. Pei Li, Qing Liu, Qingke Kong*, reversible synthesis of colonic acid and O-antigen polysaccharide in Salmonella Typhimurium enhances induction of cross-immune responses and protection against heterologous Salmonella challenge, Vaccine, 2017 35 (21): 2862-2869.
7. Qiong Liu, Qing Liu, Kenneth L. Roland, Qingke Kong*. Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model, International Journal of Medical Microbiology, 2016.
8. Qiong Liu, Qing Liu, Roy Curtiss III, Qingke Kong*. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge, Scientific Report, 2016, srep34776.
9. Chun Huang, Qing Liu, Pei Li, Qingke Kong*. Regulated delayed synthesis of lipopolysaccharide and enterobacterial common antigen of Salmonella Typhimurium enhances immunogenicity and cross-protective efficacy against heterologous Salmonella challenge, Vaccine, 2016, publication online (IF=3.413).
10. Xinxin Zhao, Qing Liu, Kangpeng Xiao, Qingke Kong*. Identification of the crp gene in avain Pasteurella multocida and evaluation of the effects of crp deletion on its phenotype, virulence and immunogenicity, BMC Microbiol, 2016, 16(1):125 (IF=2.581).
11. Yi Ren, Agata Palusiak, Wei Wang, Yi Wang, Xiao Li, Huiting Wei, Qingke Kong, Antoni Rozalski, Zhi Yao and Quan Wang*. A high-resolution typing assay for uropathogenic Escherichia coli based on fimbrial diversity, Front Microbiol, 2016, 7: 623 (IF=4.165).
12. Xueyan Liu, Qing Liu, Kangpeng Xiao, Qingke Kong*. Attenuated Salmonella Typhimurium delivery of a novel DNA vaccine induces immune responses and provides protection against duck enteritis virus, Vet Microbiol, 2016, 186:189-98 (IF=2.564).
13. Qiong Liu, Qing Liu, Xinxin Zhao, Qingke Kong*. Immunogenicity and Cross-Protective Efficacy Induced by Outer Membrane Proteins from Salmonella Typhimurium Mutants with Truncated LPS in Mice, International Journal of Molecular Sciences, 2016, 17(3) (IF=3.257).
14. Xinxin Zhao, Qing Liu, Jie Zhang, Qingke Kong*. Identification of a gene in Riemerella anatipestifer CH-1 that contributes to resistance to polymyxin B and evaluation of its mutant as a live attenuated vaccine, Microb Pathog, 2016, 91: 99-106 (IF=1.888).
15. Kangpeng Xiao, Qing Liu, Xueyan Liu, Qingke Kong*. Identification of the avian Pasteurella multocida phoP gene and evaluation of the effects of phoP deletion on virulence and immunogenicity, International Journal of Molecular Sciences, 2015, 17(1) (IF=3.257).
16. Qiong Liu, Yanyan Li, Xinxin Zhao, Qing Liu, Qingke Kong*. Construction of Escherichia coli mutant with decreased endotoxic activity by modifying lipid A structure, Mar Drugs, 2015, 13 (6): 3388-406 (IF=3.345).
17. Yanlong jiang, Qingke Kong, Kenneth L Roland, Roy Curtiss III*. Membrane vesicles of Clostridium perfringens Type A strains induce innate and adaptive immunity, International Journal of Medical Microbiology, 2014, 304(3-4): 431-43 (IF=3.898).
18. Yanlong jiang, Qingke Kong, Kenneth Roland, Roy Curtiss III*. Multiple effects of Escherichia coli Nissle 1917 on growth, biofilm formation and inflammation cytokines profile of Clostridium perfringens type A strain CP4, Pathog Dis, 2014, 70(3): 390-400 (IF=2.483).
19. Wang S, Kong Q, Curtiss R, 3rd* (2012) New technologies in developing recombinant attenuated Salmonella vaccine vectors. Microb Pathog, 58: 17-28 (IF=1.888).
20. Luo Y, Kong Q, Yang J, Mitra A, Golden G, et al. (2012) Comparative genome analysis of the high pathogenicity Salmonella Typhimurium strain UK-1. PLoS One 7: e40645 (IF=3.057).
21. Kong Q, Six DA, Liu Q, Gu L, Wang S, et al. (2012) Phosphate groups of lipid A are essential for Salmonella enterica serovar Typhimurium virulence and affect innate and adaptive immunity. Infect Immun 80: 3215-3224 (IF=3.603).
22. Luo Y, Kong Q, Yang J, Golden G, Wanda SY, et al. (2011) Complete genome sequence of the universal killer Salmonella enterica Serovar Typhimurium UK-1 (ATCC 68169). J Bacteriol 193: 4035-4036 (IF=3.198).
23. Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, et al. (2011) Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar typhimurium. Infect Immun 79: 4227-4239 (IF=3.603).
24. Kong Q, Six DA, Roland KL, Liu Q, Gu L, et al. (2011) Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. J Immunol 187: 412-423 (IF=4.985).
25. Kong Q, Six DA, Liu Q, Gu L, Roland KL, et al. (2011) Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant. Infect Immun 79: 5027-5038 (IF=3.603).
26. Kong Q, Liu Q, Jansen AM, Curtiss R, 3rd (2010) Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Vaccine 28: 6094-6103 (IF=3.413).
27. Kong Q, Liu Q, Roland KL, Curtiss R, 3rd (2009) Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect Immun 77: 5572-5582 (IF=3.603).
28. Wang L, Liu B, Kong Q, Steinruck H, Krause G, et al. (2005) Molecular markers for detection of pathogenic Escherichia coli strains belonging to serogroups O 138 and O 139. Vet Microbiol 111: 181-190 (IF=2.564).
29. Guo H, Kong Q, Cheng J, Wang L, Feng L (2005) Characterization of the Escherichia coli O59 and O155 O-antigen gene clusters: the atypical wzx genes are evolutionary related. FEMS Microbiol Lett 248: 153-161 (IF=1.858).
30. Beutin L, Kong Q, Feng L, Wang Q, Krause G, et al. (2005) Development of PCR assays targeting the genes involved in synthesis and assembly of the new Escherichia coli O 174 and O 177 O antigens. J Clin Microbiol 43: 5143-5149 (IF=3.631).
31. Kong Q, Guo HJ, Zhao G, Guo X, Cheng JS, et al. (2004) Sequence of Escherichia coli O141 O-antigen gene cluster and analyses of its evolutionary history. Journal of Genetics and Genomics, 31: 1448-1454 (IF=3.981).
研究方向与兴趣:
1. 应用研究领域主要是人用或兽用疫苗开发，重点在人畜共患病病原细菌的疫苗研发。包括目前主要开展的在重组减毒沙门疫苗及疫苗载体的构建，及针对其它病原菌及癌症或其它自身免疫疾病如糖尿病等的减毒疫苗及亚单位疫苗（重组蛋白，重组多糖，外膜蛋白及外膜微囊体等）的研发。
2. 基础研究领域主要涉及人畜共患病病原细菌的致病机理，重点在细菌多糖及表面附属物调控宿主相互作用的机理方面，包括目前开展的沙门氏菌及其它致病性细菌脂多糖合成途径的调控网络分析和脂多糖尤其是lipid A改变对细菌致病性及与宿主的关系影响，及其它多糖对沙门菌的致病性影响及它们之间的相互作用;动物微生物菌群与减毒活疫苗及宿主的相互作用等。
3. 人畜共患病病原细菌快速检测方法的开发及检测性抗体及治疗性抗体的研发。
4. 合作研究。
欢迎有意向合作的企业来电联系洽谈合作事宜；
欢迎有志于疫苗开发及微生物致病性研究的有志学生报考本实验室的硕士及博士研究生；
也欢迎有意向博士后合作的博士毕业生联系本实验室。Email: kongqiki(at)swu.edu.cn or kongqiki(at)163.com.
